Company research
MBX Biosciences, Inc.
CIK 1776111Updated Sep 24, 2026
SecurityMBX · NASDAQ · equity
MBX price & chart
Loading TradingView…
NASDAQ:MBX on TradingView ↗About the company
We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEP™, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. Our PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. We are advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. Our product candidates and programs include:
In the news
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth ↗
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
SCHEDULE 13G/A filing
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure · Other Events
Items 2.02, 7.01, 8.01, 9.01
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 385,144,000Source | 268,535,000Source | 84,180,000Source |
| Property, Plant and Equipment, NetUSD | 2,735,000Source | 1,080,000Source | 439,000Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 75,289,000Source | 49,351,000Source | 30,523,000Source |
| Assets, CurrentUSD | 381,539,000Source | 267,286,000Source | 83,465,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,834,000Source | 5,137,000Source | 2,789,000Source |
| Operating Lease, Right-of-Use AssetUSD | 487,000Source | 119,000Source | 226,000Source |
| Other Assets, NoncurrentUSD | 383,000Source | 50,000Source | 50,000Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 15,921,000Source | 11,093,000Source | 4,291,000Source |
| Stockholders’ equity: | |||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 6,000Source | 5,000Source | 1,000Source |
| Retained Earnings (Accumulated Deficit)USD | -224,476,000Source | -137,505,000Source | -75,583,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 286,000Source | 55,000Source | 60,000Source |
| Stockholders' Equity Attributable to ParentUSD | 369,223,000Source | 257,442,000Source | -72,468,000Source |
| Additional Paid in Capital, Common StockUSD | 593,407,000Source | 394,887,000Source | 3,054,000Source |
| Liabilities and EquityUSD | 385,144,000Source | 268,535,000Source | 84,180,000Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 15,495,000Source | 11,051,000Source | 3,926,000Source |
| Operating Lease, Liability, CurrentUSD | 172,000Source | 171,000Source | 153,000Source |
| Accounts Payable, CurrentUSD | 2,977,000Source | 5,335,000Source | 1,391,000Source |
| Operating Lease, Liability, NoncurrentUSD | 424,000Source | 0Source | 171,000Source |
| Additional Financial Items | |||
| Accrued Liabilities, CurrentUSD | 12,346,000Source | 5,545,000Source | 2,382,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 373,700,000Source | 262,100,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -86,971,000Source | -61,922,000Source | -32,563,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 8,677,000Source | 5,222,000Source | 2,043,000Source |
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in Accounts PayableUSD | -2,456,000Source | 3,927,000Source | 412,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -79,949,000Source | -54,681,000Source | -31,978,000Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -83,705,000Source | -160,595,000Source | -30,927,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,929,000Source | 874,000Source | 129,000Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 189,592,000Source | 234,104,000Source | 69,218,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 25,938,000Source | 18,828,000Source | 6,313,000Source |
| Additional Financial Items | |||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 373,700,000Source | 262,100,000Source | — |
| DepreciationUSD | 248,000Source | 244,000Source | 157,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | -69,000Source |
| General and Administrative ExpenseUSD | 18,896,000Source | 10,779,000Source | 6,777,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -86,971,000Source | -61,922,000Source | -32,563,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -86,971,000Source | -61,922,000Source | -32,563,000Source |
| Operating ExpensesUSD | 98,055,000Source | 68,194,000Source | 35,311,000Source |
| Operating Lease, ExpenseUSD | 300,000Source | 200,000Source | 200,000Source |
| Proceeds from Issuance of Common StockUSD | 601,700,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | 2,415,000Source | 403,000Source | 739,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Operating Income (Loss)USD | -98,055,000Source | -68,194,000Source | -35,311,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -87,000,000Source | — | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -86,971,000Source | -61,922,000Source | -32,563,000Source |
| Earnings Per Share, BasicUSD per share | -2.38Source | -5.82Source | -31.96Source |
| Earnings Per Share, DilutedUSD per share | -2.38Source | -5.82Source | -31.96Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 36,506,092Source | 10,642,954Source | 1,018,757Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 36,506,092Source | 10,642,954Source | 1,018,757Source |
| Additional Financial Items | |||
| General and Administrative ExpenseUSD | 18,896,000Source | 10,779,000Source | 6,777,000Source |
| Interest and Other IncomeUSD | 11,084,000Source | 6,272,000Source | 2,748,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -86,971,000Source | -61,922,000Source | -32,563,000Source |
| Operating ExpensesUSD | 98,055,000Source | 68,194,000Source | 35,311,000Source |
| Operating Lease, ExpenseUSD | 300,000Source | 200,000Source | 200,000Source |
| Research and Development ExpenseUSD | 79,159,000Source | 57,415,000Source | 28,534,000Source |
Offerings
Registration 333-290447
- Gross proceeds
- 199944990.0
- Net proceeds
- 187948291.0
- Deal price
- 18.0
- Shares
- 11108055
- Offering price
- $18.00
- Ticker
- MBX
Filing attachments
mbx-ex99_1.htm · 8-K · 2026-08-27
EX-99.1 2 mbx-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year clinical benefit Global registrational trial to enroll approximately 160 adults with HP to support once-weekly canvuparatide’s potential as a best-in-class PTH replacement therapy CARMEL, Ind.,…
Read attachment ↗mbx-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 mbx-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights One-year data demonstrated sustained benefit of once-weekly canvuparatide as a potential PTH replacement therapy in chronic hypoparathyroidism; Phase 3 pivotal trial now recruiting Initial Phase 1 data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity, support potential for once-monthly dosing; data from 12-week MAD (Part C) on track for Q4 2…
Read attachment ↗mbx-ex99_2.htm · 8-K · 2026-08-06
EX-99.2 3 mbx-ex99_2.htm EX-99.2 Pioneering Precision Peptides for Endocrine and Metabolic Diseases August 2026 Corporate Presentation Disclaimer This presentation includes forward looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our product candidates, preclinical study and/or clinical trial timelines, including projected data announcements, future results of operations and financial position, strate…
Read attachment ↗mbx-ex99_1.htm · 8-K · 2026-06-12
EX-99.1 2 mbx-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial Results consistent with restoration of systemic PTH activity through serum calcium normalization, reduction of urine calcium excretion, restoration of…
Read attachment ↗mbx-ex99_2.htm · 8-K · 2026-06-12
EX-99.2 3 mbx-ex99_2.htm EX-99.2 ENDO 2026 Pioneering Precision Peptides for Endocrine and Metabolic Diseases June 12, 2026 EXHIBIT 99.2 Introduction Kent Hawryluk MBX President & CEO Disclaimer This presentation includes forward looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our product candidates, preclinical study and/or clinical trial timelines, including projected data announcements, future re…
Read attachment ↗mbx-ex99_1.htm · 8-K · 2026-05-11
EX-99.1 2 mbx-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, including 2 placebo) MBX 4291 generally well tolerated, only one event of diarrhea, nausea or vomiting through 8 weeks in first MAD Part B cohort MBX 42…
Read attachment ↗